NCT00833963 (MotHER) (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER) (NCT00833963)

Trial Description
The MotHER Pregnancy Registry is a U.S.-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with trastuzumab (Herceptin®;Genentech, Inc.) plus perjeta with or without pertuzumab, or ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.), during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).

This trial is sponsored by Genentech, Inc. [1]

Study Data

  • Condition:
    • Breast Cancer
    • Pregnancy
  • Interventions:
  • Phase: IV
  • Estimated Enrollment: 100
  • Start: December 2008
  • Estimated Completion: December 2022
  • Last verified: October 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 31, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.